Processing

Please wait...

Settings

Settings

1. WO2000041545 - REGULATORS OF THE PCT OR SMOOTHENED PATHWAY, COMPOSITIONS AND USES RELATED THERETO

Publication Number WO/2000/041545
Publication Date 20.07.2000
International Application No. PCT/US2000/000873
International Filing Date 13.01.2000
Chapter 2 Demand Filed 14.08.2000
IPC
A61K 31/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
A61K 31/335 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/35 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
A61K 31/352 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/4747 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4747spiro-condensed
A61K 31/56 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
CPC
A61K 31/35
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
A61K 31/56
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
A61K 31/58
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
58containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/585
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
58containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
585containing lactone rings, e.g. oxandrolone, bufalin
A61K 31/70
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Applicants
  • ONTOGENY, INC. [US/US]; 45 Moulton Street Cambridge, MA 02138, US (AllExceptUS)
  • DUDEK, Henryk [US/US]; US (UsOnly)
  • JI, Benxiu [US/US]; US (UsOnly)
Inventors
  • DUDEK, Henryk; US
  • JI, Benxiu; US
Agents
  • HALSTEAD, David, P. ; Foley, Hoag & Eliot, LLP One Post Office Square Boston, MA 02109, US
Priority Data
09/417,56414.10.1999US
60/115,64213.01.1999US
60/119,59410.02.1999US
60/142,12402.07.1999US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) REGULATORS OF THE PCT OR SMOOTHENED PATHWAY, COMPOSITIONS AND USES RELATED THERETO
(FR) REGULATEURS DE LA VOIE DE $i(HEDGEHOG), COMPOSITIONS ET PROCEDES D'UTILISATION CORRESPONDANTS
Abstract
(EN)
The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from $i(hedgehog) gain-of-function, $i(ptc) loss-of-function or $i(smoothened) gain-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule in an amount sufficient to control the aberrant growth state, e.g., to agonize a normal $i(ptc) pathway or antagonize $i(smoothened) or $i(hedgehog) activity. The present invention further makes available methods and reagents for ameliorating the consequences of $i(hedgehog) loss-of-function, $i(ptc) gain-of-function, or $i(smoothened) loss-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule, in an amount sufficient for amelioration. In certain embodiments, the subject compounds, e.g., a cAMP analog, adenylate cyclase agonist, or cAMP phosphodiesterase inhibitor, regulate cAMP levels, which in turn modulates activity of the $i(hedgehog) pathway.
(FR)
La présente invention propose des procédés et des réactifs pour inhiber les états de croissance aberrants dus au gain des fonctions de $i(hedgehog), à la perte des fonctions de $i(ptc) ou au gain des fonctions de $i(smoothened), lesdits procédés consistant à mettre une cellule en contact avec un composé tel qu'un polypeptide ou une petite molécule dans des quantités suffisantes pour contrôler l'état de croissance aberrant, à savoir pour servir d'agoniste à une voie $i(ptc) normale ou d'antagoniste à une activité de $i(smoothened) ou de $i(hedgehog). En outre, la présente invention propose des procédés et des réactifs pour améliorer les conséquences du gain des fonctions de $i(hedgehog), de la perte des fonctions de $i(ptc) ou du gain des fonctions de $i(smoothened), qui consistent à mettre une cellule en contact avec un composé tel qu'un polypeptide ou une petite molécule dans des quantités suffisantes pour donner de meilleurs résultats. Dans certains modes de réalisation, les composés de l'invention, p.ex., cAMP, agoniste d'adénylate cyclase ou inhibiteur de phosphodiestérase cAMP régulent les niveaux de cAMP qui, à son tour, module l'activité de la voie $i(hedgehog).
Latest bibliographic data on file with the International Bureau